Page 2 - இந்தியன் மருந்து உற்பத்தியாளர் சங்கம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Is it time to rethink PSE policy? × Yes, especially in the pharma space where public sector units have the infrastructure, manpower and technical expertise Recently, the government said that it will be using three public sector enterprises for manufacturing Covaxin to augment the manufacturing capacity under Mission COVID Suraksha. These were Haffkine Biopharmaceutical Corporation Ltd, a State public sector enterprise (PSE) under the Maharashtra government; Indian Immunologicals Ltd (IIL), Hyderabad a facility under National Dairy Development Board; and Bharat Immunologicals and Biologicals Corporation Ltd (BIBCOL), Bulandshahr, a CPSE under the Department of Biotechnology. Why this late, many ask. It has also revived the debate on the relevance of PSEs and also whether the government needs to revisit its thinking on ‘Minimising presence of PSEs’ and creating new investment space for the private sector.

Uttar pradeshAndhra pradeshBharat immunologicalsIndian immunologicals ltdNational dairy development boardBiologicals corporation ltdStanding conference of public enterprisesNational list of essential medicinesCentre or statesIndian drug manufacturer associationDepartment of biotechnologyHaffkine biopharmaceutical corporation ltdMinistry of commenceAtul sobtiStanding conferencePublic enterprises